

**TESTING OF THE GUIDANCE ON
RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS**

Latin America Training Course on Risk Assessment of LMOs, Havana, Cuba, 7-11 November 2011

PARTICIPANT 1

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
<u>Please indicate the level of agreement you attribute to each of the questions in the left column.</u>					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a <u>scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: No en este momento.

Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap? Yes No Comments: Más o menos.

PARTICIPANT 2

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
<u>Please indicate the level of agreement you attribute to each of the questions in the left column.</u>					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Es necesario una rigurosa revisión científica.
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Para países con poca experiencia podría ayudarlos de alguna forma.
Q10. Is the Roadmap organized in a logic and structured manner?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Hay que reducir la cantidad de texto que tienen ejemplos. Es necesario más textos.
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: El texto no contempla novas tecnologías.
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: No, pero existe tantas nuances en casa escala que queda imposible consideralas en un solo marco.
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Sí, nuevos avances como vacunas, microRNA.

Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap? Yes No Comments: El flujo es diseñado para el texto.

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the “Guidance on Risk Assessment of Living Modified Organisms” below.

- Q31. 1. Sugiero que se incluan términos sobre nuevos avances como vacunas, microRNA, etc.
 2. Además, hay mucho testo que puede hacer lio a las ideas principales de los par'agrafos.
 3. Una mayor clarificatíon para "(near-)isogenic".

PARTICIPANT 3

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
--	-----------	------	---------	------	-----------

Please indicate the level of agreement you attribute to each of the questions in the left column.

Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
--	--------------------------	--------------------------	-------------------------------------	--------------------------	--------------------------

Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a <u>scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
--	--------------------------	--------------------------	--------------------------	-------------------------------------	--------------------------

Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
---	--------------------------	--------------------------	-------------------------------------	--------------------------	--------------------------

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol? Yes No Comments: Pero deve ser mejorada.

Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment? Yes No Comments:

Q10. Is the Roadmap organized in a logic and structured manner? Yes No Comments:

Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity? Yes No Comments:

Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Eso depende de las medidas de gestion.
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Desarrollo de la interaccion con el sistema teniendo en cuenta manejo cultural y relaciones ecosistemicas.
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the “Guidance on Risk Assessment of Living Modified Organisms” below.

- Q31. 1. Para el caso de paises en desarrollo generalmente no contamos con una línea base, ni hemos identificado un punto final, ni tenemos una política ambiental respecto al uso de OVM. Por ende, podría la guía dar otra opción como puede ser.
2. Iniciar evaluaciones puntuales de acuerdo con el medio receptor.

PARTICIPANT 4

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
<u>Please indicate the level of agreement you attribute to each of the questions in the left column.</u>					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a <u>scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Preocupación sobre el estado de la guía, ya que si es un complementeo del Protocolo de Cartagena artículo 15 y Anexo III, si hay algun tema o asunto que la Parte no pueda usar o no utilice en la evaluación del riesgo a nivel nacional, no estaria en
---	--	--

concordancia con el Protocolo de Cartagena.

Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:

PARTICIPANT 5

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
<u>Please indicate the level of agreement you attribute to each of the questions in the left column.</u>					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a <u>scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:

PARTICIPANT 6

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a <u>scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments?

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the “Guidance on Risk Assessment of Living Modified Organisms” below.

Q31. Era necesario tener más tiempo para revisar más tranquilamente esta guía. Además hubiera sido adecuado poder revisar la parte 2 y parte 3.

PARTICIPANT 7

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good

Please indicate the level of agreement you attribute to each of the questions in the left column.

Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III? Very poor Poor Neutral Good Very good

Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a scientifically sound and case-by-case manner? Very poor Poor Neutral Good Very good

Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments? Very poor Poor Neutral Good Very good

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol? Yes No Comments:

Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment? Yes No Comments:

Q10. Is the Roadmap organized in a logic and structured manner? Yes No Comments:

Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity? Yes No Comments:

Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)? Yes No Comments:

Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)? Yes No Comments:

Q14. Is there any other issue or concept that you would like to see included in the Roadmap? Yes No Comments:

Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap? Yes No Comments: El diagrama de flujo no explica claramente como proceder. Por ejemplo, debe ser un diseño vertical donde los "overarching issues" abarque o se entienda que se deben tener en cuenta en todo el proceso de evaluación de riesgo.

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the “Guidance on Risk Assessment of Living Modified Organisms” below.

Q31. La guía ha sido muy útil porque explica mejor la práctica como proceder en el anexo 3 del Protocolo, te enfoca como empezar, que aspectos se deben tener en cuenta siempre y como concluir la evaluación de riesgo.

PARTICIPANT 8

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
<u>Please indicate the level of agreement you attribute to each of the questions in the left column.</u>					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:

Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the "Guidance on Risk Assessment of Living Modified Organisms" below.

- Q31.
1. Sobre las incertidumbres propongo diferenciar las asociadas a la información y las correspondientes a la variabilidad del sistema experimental.
 2. Acerca del monitoreo, considero que se debe distinguir el monitoreo sobre: el OVM, especies no blanco y otros efectos adversos sobre el ecosistema.
 3. En aspectos relacionados con la toma de decisiones, se propone adicionar el análisis de costos y beneficios.
 4. Sobre la selección de comparadores, proponemos esclarecer cuales se consideran casi-isogénicos, los usos de los comparadores en general y proponer comparadores para los "stacks" obtenidos por cruzamiento de parentales que son OVMs.

PARTICIPANT 9

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
<u>Please indicate the level of agreement you attribute to each of the questions in the left column.</u>					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a <u>scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Requiere experiencia en evaluación de riesgos de OVM.

Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Faltan ejemplos para microorganismos.
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Debría reestructurar su formato.

PARTICIPANT 10

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
<u>Please indicate the level of agreement you attribute to each of the questions in the left column.</u>					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a <u>scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS					

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:

Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:

PARTICIPANT 11

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
<u>Please indicate the level of agreement you attribute to each of the questions in the left column.</u>					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Creo que hay que tener experiencia amplia para aplicarlo.

Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Queda muy claro que es complejo.
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Logicamente algunos casos son más complejos pero es válido.
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments:
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Falta esclarecer algunos conceptos como monitoreo y incertidumbre.

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the “Guidance on Risk Assessment of Living Modified Organisms” below.

Q31. Creo que para el análisis no existe ninguna receta "muy buena". Es un proceso demasiado complejo.

PARTICIPANT 12

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
Please indicate the level of agreement you attribute to each of the questions in the left column.					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a <u>scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: El Protocolo de Cartagena Anexo 3 8f es claro y refiere que la incertidumbre es algo transversal y est'a presente en todas las etapas y no se discuten este tema.
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Esta diseñado para personas con experiencia.
Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Mejorar su construcción.
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Los ejemplos.
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Microorganismos no estan muy claro.
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Separar decisiones con evaluación de riesgo.
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Hay que separar toma de decisiones y la evaluación de riesgo. Estructurarlo más claro.

PARTICIPANT 13

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner?</u>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments?

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Sin embargo, hay algunas ideas que deben ser enriquecidas.
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: En algunos casos suelen ser un poco complicada en cuanto a interpretación.
Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Me parece que debe ser revisada y mejorada.
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Sí, pero se necesitan esclarecer algunas ideas.
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Me parece que el enfoque se ha quedado un poco corto.
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Aplica el comentario anterior.
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Hay que enriquecer y adicionar algunas definiciones.
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Me parece que es una muy buena herramienta.

PARTICIPANT 14

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
--	-----------	------	---------	------	-----------

Please indicate the level of agreement you attribute to each of the questions in the left column.

Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?

Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a scientifically sound and case-by-case manner?

Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments?

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol? Yes No Comments:

Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment? Yes No Comments:

Q10. Is the Roadmap organized in a logic and structured manner? Yes No Comments:

Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity? Yes No Comments:

Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)? Yes No Comments:

Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)? Yes No Comments:

Q14. Is there any other issue or concept that you would like to see included in the Roadmap? Yes No
 Comments: Valdría la pena incluir de alguna manera la necesidad de conocer aspectos relativos a agricultura tradicional. Estos aspectos son importantes en centros de origen. Además definir centros de origen y centros de diversidad.

Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap? Yes No
 Comments: Es necesario mostrar que los aspectos relevantes ("overarching issues") son transversales a todas las demás etapas del proceso.

PARTICIPANT 15

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good

Please indicate the level of agreement you attribute to each of the questions in the left column.

Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III? Very poor Poor Neutral Good Very good

Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a scientifically sound and case-by-case manner? Very poor Poor Neutral Good Very good

Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments? Very poor Poor Neutral Good Very good

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol? Yes No Comments:

Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment? Yes No Comments:

Q10. Is the Roadmap organized in a logic and structured manner? Yes No Comments: Pero le falta todavia organizaci3n y informaci3n t3cnica.

Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity? Yes No Comments:

Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)? Yes No Comments:

Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)? Yes No Comments:

Q14. Is there any other issue or concept that you would like to see included in the Roadmap? Yes No Comments:

Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap? Yes No Comments: Le falta mucho simplificarlo.

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the “Guidance on Risk Assessment of Living Modified Organisms” below.

Q31. Q6 & Q7. It still needs organization.

1. En el "Use of terms" poner una referencia describiendo bien lo que es el "centro de origen" para evitar confusiones, especialmente en el contexto nacional.
2. Al momento de elaborar las traducciones, importante un buen editor técnico. Por ejemplo, las traducciones al español de "analysis", "evaluation" (evaluación??), assessment (evaluación??), "monitoring" (monitoreo? vigilancia??).
3. Tratar de colocar los ejemplos al pie de página, ya que se est'an incluídos dentro de todo el texto, distraen de la idea principal.
4. En la medida que sea possible, involucrar los expertos que enriquezcan las revisiones y el documento.

PARTICIPANT 16

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
<u>Please indicate the level of agreement you attribute to each of the questions in the left column.</u>					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: El Protocolo de Cartagena Anexo 3 para 8f es claro la incertidumbre es "transversal" y no se discute ese tema. Se esto no se resuelvexxxxxxx
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Requiere de conoscimineto y "experiencia" para adivinar lo que se pretende a cada paso; demasiadas palabras para decir un tema.
Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Mejor consistencia. a) Forma: Los ejemplos distraen el objetivo de la evaluación de riesgo. Llevar a pie de página los ejemplos; revisar las definiciones de otras organizaciones e el flujo de la estructura. b) Fondo: Evitar términos juridicos, o de acuerdo

que restan; objetividad y realizar una separación entre decisión y evaluación de riesgo; Evitar direccionar en una o otra posición.

Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Los ejemplos.
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Esta centrado en temas de "Bt" y "RR", la tecnología avanza y nos enfrena a nuevos eventos como el frijol de Brasil.
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: No considera aspectos de simplificación cuando el OVM está en etapa experimental.
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Diferenciar cuando termina la ER y la Decisión empieza y clarificar el flujo.
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Establece las etapas; si mejora la interpretación Q14 podría ser positiva.

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the "Guidance on Risk Assessment of Living Modified Organisms" below.

- Q31. 1. El objetivo de esta guía es exclusivamente de evaluación de riesgo cuando se discute o agrega en español el análisis de riesgo es el contexto de la decisión y el AHTEG debe realizar el esfuerzo científico para separar.
2. Una vez separado ER de Decisión se deberá clarificar esta etapa.
3. Revisar los títulos y el editor científico sea objetivo.
4. Considerar la experiencia de monitoreo de Brazil y Mexico.

PARTICIPANT 17

OVERALL EVALUATION

	Very poor	Poor	Neutral	Good	Very good
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a <u>scientifically sound and case-by-case manner</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with “yes” or “no” and add comments if needed.

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q10. Is the Roadmap organized in a logic and structured manner?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments:
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Comments: Estoy de acuerdo de incluir lo discutido en el taller; gen producto ampliado.
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Comments: Se podria hacer visual el flujo y tambien separando la evaluación de riesgo de la toma de decisiones.

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the “Guidance on Risk Assessment of Living Modified Organisms” below.

Q31. La importancia para nuestros paises de definir centro de origen.
